Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China

/PRNewswire/ -- Life Molecular Imaging (LMI) and Sinotau Pharmaceutical Group are pleased to announce Neuraceq® (with Chinese trade name 欧韦宁®, florbetaben F-18...

Related Keywords

Johannesburg ,Gauteng ,South Africa ,Beijing ,China ,Sichuan ,Gansu ,Guangdong ,Jilin ,Xinsheng Xu ,Jiangsu ,Berlin ,Germany ,United States ,United Kingdom ,Shanghai ,South African ,Chinese ,Ludger Dinkelborg ,Colleen Ruby ,National Medical Products Administration ,Johannesburg Stock Exchange ,Healthcare Products Regulatory Agency ,Drug Administration ,European Medicines Agency ,Life Healthcare Group ,Brittany Hahn Marketing Communications ,Sinotau Pharmaceutical Group ,First Amyloid ,Received Regulatory Approval ,Molecular Imaging ,Managing Director ,Life Molecular ,Chief Operating Officer ,Sinotau Pharmaceutical ,Positron Emission Tomography ,Safety Information ,Image Interpretation ,Life Molecular Imaging ,Piramal Imaging ,Bayer Pharma ,Life Healthcare ,Johannesburg Stock ,Marketing Communications Manager ,